Viewing nowCombinationGlyzenta Duo Extended Release Tablet 2.5/1000 mg (Linagliptin, Metformin Hydrochloride)
Metformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.

MFDS item code 202400633 · Approved 2024.03.25 · Insurance code 654006180
Improvement of glycemic control in type 2 diabetes mellitus
This medicine is used to assist patients with type 2 diabetes in managing their blood sugar levels alongside dietary and exercise therapy. It helps effectively improve blood sugar levels, particularly through the combination of Linagliptin and Metformin. Therefore, taking this medicine alongside regular meals and exercise will greatly aid in blood sugar management.
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain the extended-release properties, swallow this drug whole; do not split, crush, grind, or chew it. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. If the patient is not currently being treated with metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. If the patient is being treated with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, the initial dose of this drug should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. When this drug is administered concomitantly with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and dosage adjustments should be made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be the current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dosage adjustment according to renal function is necessary, assessment of renal function is recommended before and periodically after administration of this drug. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.
This medicine assists in controlling blood sugar levels, with the active ingredients being Linagliptin and Metformin Hydrochloride. It can rarely cause a serious metabolic disorder called lactic acidosis, which can become life-threatening if treatment is delayed. This medicine should not be administered to certain patients, such as those with allergies to this medicine, type 1 diabetes patients, patients with severe kidney impairment, and patients with poor liver function. Additionally, it is advisable for patients in acute conditions, such as dehydration, severe infections, heart disease, and acute myocardial infarction, to avoid using this medicine. When using this medicine, caution should be taken regarding the risk of hypoglycemia, especially when used together with insulin or sulfonylureas, as blood sugar levels may drop too low. To reduce the risk of lactic acidosis, kidney function should be regularly monitored, and if kidney function is impaired, the use of this medicine should be discontinued. This medicine should be suspended for a certain period during surgeries or radiological examinations and resumed only after kidney function has recovered post-surgery. When taking this medicine, do not crush or chew the tablet; it should be swallowed whole, and it is normal for the tablet shell to be excreted in the stool. Women who are pregnant or planning to become pregnant should avoid this medicine, and those who are breastfeeding should not use it either for safety reasons. When administered to elderly patients, careful observation of kidney function is important to determine the appropriate dosage. While using this medicine, side effects such as gastrointestinal disturbances, hypoglycemia, pancreatitis, and skin rashes may occur; if any unusual symptoms appear, consult a doctor immediately. Furthermore, this medicine may interact with other medications, so if you are taking any other medications, be sure to inform your healthcare provider, especially if those medications may affect kidney function. Lastly, in the case of an overdose, serious side effects such as lactic acidosis may occur, requiring immediate hospital treatment. This medicine should be stored out of reach of children and kept away from moisture.
Severe lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity reaction, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemic symptoms, taste disorders, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer, abnormal liver function tests, hepatitis, pruritus, erythema, rash, pemphigus-like eruption, joint pain accompanied by severity and disability, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, colorectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, affective disorder, insomnia, depression, contusion, bone bruise, concussion, fracture, hand fracture, palpitations, dry eye, glaucoma, cataract, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, hematuria, hypotension, flushing, fatty liver disease, cholelithiasis, hearing loss, erectile dysfunction, goiter, anemia, nausea, gastroesophageal reflux disease, headache, drowsiness, chest discomfort, asthenia, pain, nosebleed, oropharyngeal pain, speech disorder, allergic rhinitis, exertional dyspnea, wet cough, rhinorrhea, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased triglycerides in the blood, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased potassium in the blood, increased creatinine in the blood, increased creatine phosphokinase in the blood, increased ALT, male pattern baldness, hyperhidrosis, dermatitis, confusion state, nocturia, dermatitis, hypertension
Not everyone experiences these, and they can vary from person to person.
This medicine is sensitive to air and moisture, so it should be stored in a tightly closed container. Additionally, it is important to maintain its effectiveness by storing it at a cool room temperature, between 1 and 30 degrees Celsius.
This medicine is a white, oval, extended-release film-coated tablet.
30 tablets/bottle, 30 tablets/box [(6 tablets/PTP x 5)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Aju Pharmaceuticals Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.